Baird lowered the firm’s price target on Enanta (ENTA) to $20 from $26 and keeps an Outperform rating on the shares. The firm said the Q4 report was straightforward, and noted they are on the precipice of the crucial RSVPEDs readout in December, which Baird thinks will be the key determinant of zelicapavir’s future potential in RSV.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ENTA:
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue